Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells.
Isono M, Sato A, Asano T, Okubo K, Asano T.
Anticancer Res · journal article · DOI 10.21873/anticanres.12620 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för delanzomib. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
9 hitsNovel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway.
Guo KY, Han L, Li X, Yang AV, Lu J, Guan S, Li H, Yu Y, Zhao Y, Yang J, Zhang H.
Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.23166Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.
Vogl DT, Martin TG, Vij R, Hari P, Mikhael JR, Siegel D, Wu KL, Delforge M, Gasparetto C.
Leuk Lymphoma · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1080/10428194.2016.1263842A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte A, Martinelli G, Böhm S, Driessen C, De Braud F, Marsoni S, Cereda R, Sala F, D'Incalci M, Sessa C.
Eur J Cancer · research support, non-u.s. gov't; clinical trial, phase i; review; journal article · DOI 10.1016/j.ejca.2012.09.009CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
Sanchez E, Li M, Li J, Wang C, Chen H, Jones-Bolin S, Hunter K, Ruggeri B, Berenson JR.
Leuk Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.leukres.2012.07.018Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
Seavey MM, Lu LD, Stump KL, Wallace NH, Ruggeri BA.
Int Immunopharmacol · journal article · DOI 10.1016/j.intimp.2011.11.019Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study.
Sala F, Marangon E, Bagnati R, Livi V, Cereda R, D'Incalci M, Zucchetti M.
J Mass Spectrom · journal article · DOI 10.1002/jms.1842The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
Sanchez E, Li M, Steinberg JA, Wang C, Shen J, Bonavida B, Li ZW, Chen H, Berenson JR.
Br J Haematol · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1365-2141.2009.08008.xCEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Strepponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaa H, Bernareggi A, Inghirami G.
Blood · research support, non-u.s. gov't; journal article · DOI 10.1182/blood-2007-07-100651